As a reminder, DKI owned scPharma because we were positive on its product Furoscix as well as the likely approval of its autoinjector. We thought the company would be acquired. It was purchased last year by MannKind for cash and a contingent value right (CVR). For more details on the CVR, check out the post … Read more
Intel crushes estimates and raises guidance. Results in the 18A plant are ahead of expectations. They increase the cap-x budget to meet profitable demand. Yet the stock fall. We explain. In recent weeks, we’ve taken on the issue of personal ownership of purchased goods. President Trump is addressing the right to repair issue in favor … Read more
Intel announced fantastic 2Q results after the close today. Revenue of $16.1B was up 25% and crushed analyst estimates of $14.5B. Prior guidance had been for $13.8B – $14.8B. Adjusted EPS of $.42 was also far above analyst estimates of $.22. Prior guidance had been for $.20. Gross margin of 40.4% was above last year’s … Read more
Quick announcement: I’m off and working from new locations for another year. I’ll be in Antigua, Guatemala for the next few weeks. While I’m here, I’m open to a small number of in-person conversations. If you’re based locally, or know someone here you think it would be worthwhile for me to meet, feel free to … Read more
